CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

详细信息    查看全文

• 作者：Frederick L. Locke¹ ; Joseph Pidala¹ ; Barry Storer² ; Paul J. Martin² ; ³ ; Michael A. Pulsipher⁴ ; Thomas R. Chauncey³ ; ⁵ ; Niels Jacobsen⁶ ; Nicolaus Krö ; ger⁷ ; Irwin Walker⁸ ; Susan Light⁹ ; Bronwen E. Shaw¹⁰ ; Francisca Beato¹ ; Ginna G. Laport¹¹ ; Auayporn Nademanee¹² ; Armand Keating¹³ ; Gerard Socie¹⁴ ; Claudio Anasetti¹ ; ^{claudio.anasetti@moffitt.org}
• 关键词：Antitumor immunity ; Daclizumab ; Regulatory T cells
• 刊名：Biology of Blood and Marrow Transplantation
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：23
• 期：3
• 页码：405-411
• 全文大小：1104 K
• 卷排序：23

文摘

It was believed that daclizumab would prevent acute graft-versus-host disease (GVHD) by blocking T cell activation. A trial of daclizumab after allogeneic transplantation did not decrease aGVHD. Follow-up showed that anti-CD25 therapy delayed regulatory T cell (Treg) repopulation after transplantation. Transient Treg reduction may have long-term effects on chronic GVHD and relapse risk. Antibody-mediated CD25 blockade may be useful in promoting antitumor immunity.